



CORPORATE HEADQUARTERS

373 Inverness Parkway
Suite 206
Englewood, CO 80112
Phone: 1.720.437.6580
www.aytubio.com

Industry: Specialty Pharmaceuticals,
Life Sciences

Year End: June 30

SHARE DISTRIBUTION

Outstanding: 5.0 million
Fully Diluted: 12.2 million

STOCK SUMMARY

Symbol: NASDAQ:AYTU
Price: (As of 1/4/18) \$2.55
Market Cap: (1/4/18) \$ 12.7 million

MANAGEMENT TEAM

Josh Disbrow
Chairman & Chief Executive Officer

Jarrett Disbrow
Chief Operating Officer

David Green
Chief Financial Officer

INVESTOR RELATIONS

Amato and Partners, LLC
90 Park Avenue, 17th Floor
New York, NY 10016
admin@amatoandpartners.com

AYTU BioScience, Inc. NASDAQ: AYTU

AYTU BioScience is a commercial-stage specialty life sciences company focused on global commercialization of novel products in the field of urology. Current product portfolio addresses low testosterone, prostate cancer, male infertility and sexual wellness.

The company currently markets Natesto nasal gel, a novel formulation of testosterone, and ProstaScint, an imaging agent for prostate cancer detection and staging. Aytu is developing MiOXSYS, a novel, rapid semen analysis system for the diagnosis and management of male infertility. Aytu also markets Fiera, a personal care device for women proven to enhance physical arousal and sexual desire.

Product Portfolio

- **Natesto** – testosterone nasal gel indicated for hypogonadism
- **MiOXSYS** – *in vitro* device for male infertility
- **Fiera** – pre-intimacy device to increase sexual desire and arousal in women
- **ProstaScint** – imaging agent for prostate cancer

Investment Highlights

- Experienced management team with proven success growing specialty pharmaceutical and life sciences companies
- Active business development for acquisition for additional urology products
- Established Urology-Focused Commercial Infrastructure
- Testosterone Market Opportunity
 - \$2 billion market in the U.S., 13 million men diagnosed with hypogonadism (low testosterone)
- Male Infertility Market Opportunity
 - \$825 million International market
 - 30 million men impacted worldwide
- Women's Sexual Health Market Opportunity
 - 53 million women in the U.S. with sexual concerns

Recent Milestones

- Announced Market Approval from the Australian Therapeutic Goods Administration for the MiOXSYS System for Male Infertility (November 2017)
- Announced up-list to NasdaqCM (October 2017)
- Announced International Distribution Agreement for Fiera in Japan (October 2017)
- Announced Reverse Split of its Common Stock (August 2017)
- Announced closing of \$11.8 million private placement of equity units (August 2017)
- Announced signing of an exclusive distribution agreement for MiOXSYS with GryNumber Health (July 2017)
- Acquired Nuelle Inc. and added Fiera personal care device to product portfolio (May 2017)

Complementary Urology Product Portfolio

Natesto

- Only FDA-approved, nasally-administered testosterone; indicated for hypogonadism (low testosterone)
- Approved for use WITHOUT black box warning related to testosterone transference, which causes male-trait enhancing side effects (e.g. hair growth, male pattern baldness) in women
- All other topical TRTs (testosterone replacement therapies) have a risk of transference as a black box warning

Natesto Phase 3 Clinical Trial

- 90-day, randomized, open-label, dose-ranging study in hypogonadal men
- Dose of 125 uL/nosril, 11.0mg testosterone/dose) self-administered either twice daily (BID) or 3 times a day (TID) for a total dose of 22.0mg or 33.0mg, respectively
- 91% of patients in TID group achieved normal testosterone levels at day 90
- Demonstrated significant improvement as early as day 30 in each of the 5 domains of erectile function; demonstrated mood improvement
- Significantly improved safety profile compared to other TRT's

MiOXSYS

- First-in-class CE Marked *in vitro* diagnostic device for male infertility
- Measures oxidative stress in male infertility cases that would otherwise go undetected with a routine semen analysis
- U.S. clinical and regulatory pathway is short and well defined
- 6 prominent U.S. study sites engaged
- Razor-razorblade commercial model with recurrent revenues from disposable sensors
- Strong global sales footprint – currently placed in 20 countries

Fiera

- First pre-intimacy device proven to increase sexual desire and arousal in women
- Utilizes two clinically validated technologies of suction and stimulation to enhance blood flow followed by feelings of “being in the mood”
- Has potential to benefit the 44.2% of women worldwide that report a sexual problem
- 53 million women in the U.S. with sexual concerns
- Developed by Nuelle – previously a portfolio company of New Enterprise Associates (NEA)

ProstaScint

- First-in class, FDA-approved radioimaging agent for prostate cancer assessment and staging
- Binds glycoprotein expressed by prostate epithelium – Prostate Specific Membrane Antigen (PSMA)
- Approved for both newly diagnosed, high-risk patients and patients suspected of having recurrent disease

Natesto
testosterone nasal gel



miOXSYS™



ProstaScint®
(Capromab Pentetide)

Management Team

Josh Disbrow, Chairman & Chief Executive Officer

Josh Disbrow has been in the life sciences industry for over twenty years across pharmaceuticals, diagnostics, and medical devices. Prior to forming Aytu BioScience, Josh was the Chief Operating Officer of Ampio Pharmaceuticals (NYSE MKT: AMPE) and led the Luoxis Diagnostics subsidiary. Luoxis was merged into Aytu in April 2015 following Luoxis' development of the technology behind the company's MiOXSYS in vitro diagnostic platform. Prior to joining Ampio in 2012, he served as Vice President of Commercial Operations at Arbor Pharmaceuticals.

Josh began as Arbor's second employee and oversaw the commercialization of the company's first product, scaling the commercial organization to over 150 people across sales, marketing, payer markets, distribution, commercial operations, and national accounts. In less than four years, Arbor grew from a company without any product revenues to a company with net sales of over \$120 million. Prior to joining Arbor, he was the Director of Marketing at LipoScience (NASDAQ: LPDX), a cardiovascular in vitro diagnostic company. Josh also served in sales management at Cyberonics (Now LivaNova plc, NASDAQ: LIVN), a medical device company commercializing implantable neuromodulation devices. Josh started his career at Glaxo Wellcome (now GlaxoSmithKline plc), holding positions in both sales and marketing. He has a Master of Business Administration from Wake Forest University and Bachelor of Science in Management from North Carolina State University.

Jarrett Disbrow, Chief Operating Officer

Jarrett Disbrow is a seasoned pharmaceutical entrepreneur having been the founder of three pharmaceutical and life sciences companies over the past decade and broad industry experience spanning over twenty years.

Most recently and prior to forming Aytu BioScience in April 2015, Jarrett was the President & CEO of Vyrix Pharmaceuticals, a specialty pharmaceutical company focused on male sexual dysfunction. Mr. Disbrow's first pharmaceutical start-up was Arbor Pharmaceuticals, a company focused initially on pediatrics. As the sole founder of Arbor, Jarrett was responsible for the vision, fundraising, start-up, strategy and growth of the company until the acquisition by an investor group in 2010. Prior to founding Arbor Pharmaceuticals, he was head of marketing for Accentia Biopharmaceuticals, Inc. Jarrett began his career with GlaxoWellcome (now GlaxoSmithKline plc) where he held various roles in sales and marketing. He received a BS in Business Management from North Carolina State University.

David Green, Chief Financial Officer

David Green has been in the life sciences industry for over twenty-five years in scientific, operating and financial advisory roles. Prior to joining Aytu BioScience, David was the Chief Accounting Officer of Intarcia Therapeutics, a biopharmaceutical company engaged in late stage clinical development, where he was involved in IPO readiness and some of the largest private financing transactions in history for a pre-commercial, venture funded, life science company. He was Chief Financial Officer of Catheter Connections, a venture financed medical device company that was acquired by Merit Medical [NASDAQ: MMSI]; and CFO of Specialized Health Products International, a publicly traded medical device company that was acquired by C.R. Bard [NYSE: BCR].

Prior to his operating roles, David advised a broad range of life science companies on issues of corporate finance and the use of strategic transactions to accelerate growth as a Managing Director of Duff & Phelps and as a member of Ernst & Young's Palo Alto *Center for Strategic Transactions*[®]. David began his career performing medical research after he received a Bachelor of Science in chemistry from the State University of New York. He holds a Masters of Business Administration in finance from the University of Rochester and is a registered CPA.

This fact sheet includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. All statements other than statements of historical facts contained in this fact sheet, including statements regarding our anticipated future clinical and regulatory events, future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. Forward looking statements are generally written in the future tense and/or are preceded by words such as "may," "will," "should," "forecast," "could," "expect," "suggest," "believe," "estimate," "continue," "anticipate," "intend," "plan," or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: risks with and future outcomes and events under our current and potential future collaborations; risks relating to gaining market acceptance of our products; obtaining reimbursement by third-party payors; the potential future commercialization of our product candidates; the anticipated start dates, durations and completion dates, as well as the potential future results, of our ongoing and future clinical trials; the anticipated designs of our future clinical trials; anticipated future regulatory submissions and events; and our anticipated future cash position. We also refer you to the risks described in "Risk Factors" in Part I, Item 1A of Aytu BioScience, Inc.'s most recent Annual Report on Form 10-K and in the other reports and documents we file with the Securities and Exchange Commission from time to time.